Polyamines and cancer: old molecules, new understanding
Top Cited Papers
Open Access
- 1 October 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (10) , 781-792
- https://doi.org/10.1038/nrc1454
Abstract
Polyamines are naturally occurring organic cations found in plants, animals and microbes. They are formed by the enzymatic decarboxylation of the amino acids ornithine or arginine. Ornithine decarboxylase (ODC) is the first enzyme in the polyamine synthesis pathway in mammals and is the target for difluoromethylornithine (DFMO), a substrate analogue and specific inhibitor that irreversibly inactivates ODC when it binds to the active site of the enzyme. ODC and several other polyamine metabolic proteins are essential for normal cell and tissue functions, including growth, development and tissue repair. ODC and polyamine content are increased in many cancers arising from epithelial tissues, such as the skin and colon. Polyamines exert their effects in eukaryotic cells in part by regulating specific gene expression. In murine and human colonic mucosal tissue, ODC is negatively regulated by the adenomatous polyposis coli (APC) tumour-suppressor gene. APC is mutated or deleted in the germline of people with familial adenomatous polyposis (FAP), a genetic syndrome associated with a high risk of colon cancer. APC is also mutated or deleted in somatic colon epithelial cells in most sporadic, or non-genetic, forms of colon cancer. Loss of APC function causes an increase in ODC activity and polyamine biosynthesis, and tumour formation in ApcMin/+ mice, a murine model of human FAP. Treatment of ApcMin/+ mice with DFMO suppresses intestinal tumour formation. Several non-steroidal anti-inflammatory drugs (NSAIDs), the use of which is associated with decreased risk of epithelial cancers, activate the transcription of spermidine/spermine N1-acetyltransferase, the first enzyme in the polyamine catabolic pathway. Experimental studies indicate that combinations of DFMO and NSAIDs are potent inhibitors of colon and intestinal cancer development in murine models. Clinical studies have shown that DFMO is well tolerated and can prevent the development of precancerous lesions in the skin. Several large randomized trials involving the skin, colon and other organ sites are underway.Keywords
This publication has 100 references indexed in Scilit:
- The chemopreventive agent α‐difluoromethylornithine blocks Ki‐ras–dependent tumor formation and specific gene expression in Caco‐2 cellsMolecular Carcinogenesis, 2004
- The role of polyamine catabolism in anti-tumour drug responseBiochemical Society Transactions, 2003
- Putrescine Activates Oxidative Stress Dependent Apoptotic Death in Ornithine Decarboxylase Overproducing Mouse Myeloma CellsExperimental Cell Research, 2002
- APC‐dependent regulation of ornithine decarboxylase in human colon tumor cellsMolecular Carcinogenesis, 2002
- A Definitive Role of Ornithine Decarboxylase in PhotocarcinogenesisThe American Journal of Pathology, 2001
- Effect of α-Difluoromethylornithine on Rectal Mucosal Levels of Polyamines in a Randomized, Double-Blinded Trial for Colon Cancer PreventionJNCI Journal of the National Cancer Institute, 1998
- Structure-activity relations of s-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cellsBreast Cancer Research and Treatment, 1996
- Dose De-escalation Chemoprevention Trial of -Difluoromethylornithine in Patients With Colon PolypsJNCI Journal of the National Cancer Institute, 1994
- Analogs of ornithine as inhibitors of ornithine decarboxylase. New deductions concerning the topography of the enzyme's active siteJournal of Medicinal Chemistry, 1977
- Methyl glyoxal bis(guanylhydrazone) as a potent inhibitor of mammalian and yeast S-adenosylmethionine decarboxylasesBiochemical and Biophysical Research Communications, 1972